Press releases

8 May, 2015

Regulatory

NeuroVive completes share issue raising SEK 70 million for the preparation of CicloMulsion®’s clinical trial in the US and commercialization in Europe

NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or the "Company", OMX:NVP) today announces that the Company has completed the directed share issue announced on May 7, 2015, whereby 1,647,059 new share ...

7 May, 2015

Regulatory

NeuroVive announces the intention to raise additional capital through a private placement

NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or the "Company", OMX:NVP) today announces that the Company intends to raise new equity through a private placement directed towards qualified instituti ...

7 May, 2015

Regulatory

Published data indicates protective effect of cyclosporine in patients with stroke

The results of a clinical phase II study indicating that cyclosporine counteracts brain injury in a subset of stroke patients undergoing thrombolysis has been published in an article co-authored by on ...

27 April, 2015

Regulatory

First patient enrolled in clinical phase II study for kidney protection during heart surgery

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that the first patient has been enrolled in a clinical phase II study for acute kidney injury using the company's prod ...

21 April, 2015

Regulatory

Clinical Phase II study with NeuroSTAT® for traumatic brain injury passes safety evaluation

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that the independent safety committee has endorsed moving on to the next dose level without any safety issues, followi ...

20 April, 2015

Regulatory

NeuroVive establishes subsidiary in Lyon and extends collaboration with HCL

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has established a subsidiary in Lyon, France. The establishment is part of a process of extending its ongoing collaboration with ...

17 April, 2015

Regulatory

Development of NVP014 for the treatment of stroke enters new phase in collaboration with Isomerase Therapeutics

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has announced that the company's development project NVP014 for the treatment of ischemic stroke is entering a new phase in coll ...

31 March, 2015

Regulatory

NeuroVive Pharmaceutical AB (publ) – amendment number of shares and votes

Pursuant to chapter 4, § 9 of the Swedish Financial Instruments Trading Act (1991:980), the company is hereby reporting that as a result of new share issue conducted by NeuroVive Pharmaceutical AB (pu ...

30 March, 2015

Regulatory

NeuroVive Pharmaceutical AB (publ): report from AGM

NeuroVive Pharmaceutical AB (publ) held its Annual General Meeting (AGM) yesterday, 30 March 2015. A summary of the resolutions follows. All resolutions were passed with the required majority.

18 March, 2015

Regulatory

NeuroVive Pharmaceutical publishes English version of annual report for 2014

NeuroVive Pharmaceutical AB (publ) today announced that the English version of the annual report for 2014 is now available on the company's website www.neurovive.com.The annual report can also be acce ...

25 February, 2015

Regulatory

Notice of Annual General Meeting of NeuroVive Pharmaceutical AB (publ)

The shareholders of NeuroVive Pharmaceutical AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 4 p.m. on Monday, 30 March 2015 at Medicon Vil ...

20 February, 2015

Regulatory

NeuroVive completes a directed share issue of SEK 65 million for continued expansion

NeuroVive Pharmaceutical AB (publ) (”NeuroVive” or the “Company”, OMX:NVP) today announces that the Company has completed a directed share issue of 1.3 million new shares, whic ...